What laboratory tests should be monitored in a patient with classic congenital adrenal hyperplasia (21‑hydroxylase deficiency)?

Laboratory Monitoring in Classic Congenital Adrenal Hyperplasia

Patients with classic CAH due to 21-hydroxylase deficiency require regular monitoring of serum 17-hydroxyprogesterone, androstenedione, plasma renin activity, and serum electrolytes to assess adequacy of glucocorticoid and mineralocorticoid replacement therapy. 1, 2

Core Biochemical Parameters

Hormonal Markers for Glucocorticoid Adequacy

• Serum 17-hydroxyprogesterone (17-OHP) is the primary marker for monitoring glucocorticoid replacement adequacy, though random measurements fluctuate significantly with time of day and timing relative to hydrocortisone administration 3, 4, 2

• Serum androstenedione provides additional assessment of androgen control and should be measured alongside 17-OHP 3, 4, 2

• Serum testosterone may be measured in females to assess hyperandrogenism, though it is less sensitive than androstenedione 3

• Random single-point hormone measurements have limited value due to marked diurnal variation; morning measurements 1-2 hours after the first hydrocortisone dose may be more informative than trough levels 3, 5

Mineralocorticoid Monitoring

• Plasma renin activity (PRA) is essential for titrating fludrocortisone dosing, with the goal of maintaining PRA in the upper-normal to slightly elevated range 1, 5, 2

• Serum electrolytes (sodium and potassium) should be checked regularly, particularly in infants and during illness, as hyponatremia occurs in ~90% of salt-wasting crises and hyperkalemia in ~50% 1, 2

• Blood pressure measurement at each visit helps detect both under-replacement (orthostatic hypotension) and over-replacement (hypertension) of mineralocorticoid 1, 5, 2

Clinical Parameters (Gold Standard)

Clinical assessment remains the gold standard for monitoring therapy adequacy and takes precedence over biochemical values when the two are discordant. 3, 2

• Growth velocity is the most sensitive indicator of glucocorticoid over-replacement in children; growth deceleration suggests excessive dosing 3, 5, 2

• Bone age assessment should be performed annually to detect premature advancement (indicating under-treatment) or delayed maturation (suggesting over-treatment) 5, 2, 6

• Body weight and BMI require monitoring at every visit, as children with CAH have increased risk of obesity, insulin resistance, and metabolic syndrome 4, 2, 6

• Pubertal staging helps identify premature adrenarche or central precocious puberty, both of which are more common in CAH 2, 6

Monitoring Frequency and Schedule

• At least annual comprehensive review should include assessment of weight, blood pressure, serum electrolytes, 17-OHP, androstenedione, and PRA 7, 1, 2

• More frequent monitoring (every 3-4 months) is warranted in infants, during periods of poor control, during puberty when hydrocortisone clearance changes, and after dose adjustments 5, 2

• Bone mineral density assessment every 3-5 years is recommended to screen for glucocorticoid-induced osteoporosis 7, 8

Alternative Monitoring Approaches

• 24-hour urine collections for pregnanetriol and 17-ketosteroids provide an integrated assessment of daily adrenal hormone production but are cumbersome and target ranges are poorly defined 3

• Daily hormonal profiles from salivary or blood-spot samples offer more detailed assessment than random measurements, though salivary assay quality is variable and this approach is not yet standard practice 3

Critical Pitfalls to Avoid

• Never rely solely on biochemical parameters to guide dosing; clinical parameters (growth, weight gain, virilization) must take precedence when biochemical and clinical findings are discordant 3, 2

• Do not aim for complete normalization of 17-OHP and androstenedione, as this typically requires supraphysiologic glucocorticoid doses that impair growth and cause Cushingoid features 2, 6

• Avoid using random single-point hormone measurements to make major treatment decisions, as they fluctuate markedly throughout the day 3

• Screen annually for associated conditions including hypothyroidism, diabetes, and other autoimmune disorders, particularly in patients with autoimmune Addison's disease 7, 8

• Monitor for complications of therapy including hypertension, hyperglycemia, dyslipidemia, and cardiovascular risk factors, which are increased in CAH patients 4, 2, 6